37 results on '"Yedilbayev, Askar"'
Search Results
2. Safety and effectiveness of three novel all-oral shortened regimens for rifampicin- or multidrug-resistant tuberculosis in Kazakhstan
3. Availability of drugs for the treatment of multidrug-resistant/rifampicin-resistant tuberculosis in the World Health Organization European Region, October 2023
4. Tuberculosis Research in European Countries: A Model for Programmatic Scale Up
5. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis
6. Screening for tuberculosis among migrants in Europe: harmonising approaches during a humanitarian crisis?
7. The impact of the war in Ukraine on the prevalence of multidrug-resistant tuberculosis in Poland: an epidemiological overview and overview of countermeasures implemented.
8. Frequency of serious adverse events on therapy with modified fully oral shorter treatment regimens (mSTR) for MDR/RR-TB
9. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB
10. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region
11. Diagnostic Capacities for Multidrug-Resistant Tuberculosis in the World Health Organization European Region
12. Integrated use of laboratory services for multiple infectious diseases in the WHO European Region during the COVID-19 pandemic and beyond
13. Corrigendum to ‘Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis’ International Journal of Infectious Diseases Volume 113S1 (2021) S91-S95
14. Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
15. Improving Outcomes for Multidrug-Resistant Tuberculosis: Aggressive Regimens Prevent Treatment Failure and Death
16. Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study
17. suNational policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for migrants among Member States of the WHO European Region.
18. Factors Associated with Unfavourable Treatment Outcomes in Patients with Tuberculosis: A 16-Year Cohort Study (2005–2020), Republic of Karakalpakstan, Uzbekistan
19. Operational Research to Inform Programmatic Approaches to the Management of Tuberculosis in Uzbekistan
20. Operational research to tackle TB in Eastern Europe and Central Asia: Moving forward during the COVID-19 pandemic
21. Outcomes of modified all-oral 9-month treatment regimen for rifampicin-resistant tuberculosis in Belarus
22. Impact of the COVID-19 pandemic on tuberculosis national reference laboratory services in the WHO European Region, March to November 2020
23. Early COVID-19 pandemic’s toll on tuberculosis services, WHO European Region, January to June 2020
24. Factors associated with culture conversion among adults treated for pulmonary extensively drug-resistant tuberculosis during 2018-2019 in the Russian Federation: an observational cohort study
25. Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18
26. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19
27. Operational research as an instrument to address the critical gaps for effective treatment of tuberculosis in eastern Europe and central Asia
28. ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis) Research Package
29. What is behind programmatic treatment outcome definitions for tuberculosis?
30. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis
31. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
32. Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe
33. Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB
34. Active case finding of tuberculosis, Tomsk (Russia)
35. Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort study.
36. National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region.
37. Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.